Azficel-T

{{Short description|Medication for nasolabial fold wrinkles}}

{{Context|date=March 2021}}

{{Use dmy dates|date=April 2020}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Infobox drug

| image =

| width =

| alt =

| caption =

| pronounce =

| tradename = Laviv

| Drugs.com = {{drugs.com|cons|azficel-t-intradermal}}

| MedlinePlus =

| DailyMedID =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration = Intradermal

| class =

| ATC_prefix = None

| ATC_suffix =

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number_Ref =

| CAS_number =

| CAS_supplemental =

| PubChem =

| IUPHAR_ligand =

| DrugBank_Ref =

| DrugBank = DB11051

| ChemSpiderID_Ref =

| ChemSpiderID =

| UNII_Ref =

| UNII = 022461SR75

| KEGG_Ref =

| KEGG =

| KEGG2_Ref =

| KEGG2 =

| ChEBI_Ref =

| ChEBI =

| ChEMBL_Ref =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms =

| IUPAC_name =

| chemical_formula =

| C= | H= | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I=

| K= | Li= | Mg= | Mn= | N= | Na= | O= | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge=

| molecular_weight =

| SMILES =

| StdInChI =

| StdInChI_comment =

| StdInChIKey =

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

Azficel-T, sold under the brand name Laviv, is a cell therapy product for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.{{cite web | title=Laviv (Azficel-T) | website=U.S. Food and Drug Administration (FDA) | date=22 July 2017 | url=https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/laviv-azficel-t | access-date=1 April 2020 | archive-date=16 December 2019 | archive-url=https://web.archive.org/web/20191216220945/https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/laviv-azficel-t | url-status=dead }}{{cite web | title=Autologous Fibroblasts | website=U.S. Food and Drug Administration (FDA) | url=https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm260485.htm | date=29 June 2017 | archive-date=22 July 2017 | archive-url=https://wayback.archive-it.org/7993/20170722071310/https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm260485.htm | url-status=unfit | access-date=1 April 2020}}{{cite web | url=https://www.fda.gov/media/80838/download | format=PDF | title=Laviv (azficel-T) Suspension for Intradermal Injection | website=Food and Drug Administration | access-date=2 April 2020 | archive-date=14 December 2019 | archive-url=https://web.archive.org/web/20191214043112/https://www.fda.gov/media/80838/download | url-status=dead }} It consists of fibroblasts harvested from the patient's own skin.

It was approved for medical use in the United States in June 2011.